Radioimmunolocalization of @entity1 XXXX : biodistribution of radiolabelled monoclonal antibody UJ13A.

@entity1 @entity5 @entity1313
Monoclonal antibody UJ13A, radiolabelled with 131I, was intravenously administered to @entity1 with primary @entity1313 . The antigen recognised by UJ13A is present on most neuroectodermally derived tissue. The ratio of uptake in @entity5 to normal brain, assessed by scintigraphy, improved with time. Maximal @entity5 uptake occurred between 4 and 48 h. Dynamic and static scintigrams indicated some early sequestration of radiolabelled antibody by the liver. @entity5 were surgically resected in seven @entity1 at various intervals after antibody administration showing tissue to blood ratios increasing with time in all parts of the lesion (viable and @entity5 , cyst fluid), and in normal brain. The highest tissue to blood ratio in viable @entity5 was 5.1 at 16 days after injection. In tissues resected 2-3 days after injection there was relatively greater uptake in the viable @entity5 compared to @entity5 and cyst fluid. In contrast, tissues resected later (6-16 days) showed greater uptake in @entity5 , suggesting diffusion was an important factor influencing @entity5 uptake. The amount of radioactivity per gram of @entity5 tissue was less than 0.005% of the injected dose. Future studies are needed using different antibodies, antibody fragments and additional methods of optimising delivery.
